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Abstract
Background: Histological malignancy grading of astrocytomas can be challenging despite criteria given by the
World Health Organisation (WHO). Grading is fundamental for optimal prognostication and treatment, and
additional biomarkers are needed to support the histopathological diagnosis. Estimation of proliferative activity has
gained much enthusiasm, and the present study was designed to evaluate and compare novel
immunohistochemical proliferative markers in human anaplastic astrocytomas.
Methods: Proliferative activity was determined in twenty-seven cases with antibodies reactive against the Ki-67
antigen, mitosin, survivin, pHH3, and DNA topoisomerase IIa, and they were mutually compared as well as related
to mitotic activity.
Results: The markers correlated well with each other, but poorly with mitoses, probably because of small and
squeezed tumour samples, in which identification of mitoses can be difficult. Positive association to overall survival
was observed as well.
Conclusions: Our data show that these markers may assist significantly in the evaluation of proliferative activity in
anaplastic astrocytomas and even have prognostic value.
Introduction
Diffuse astrocytomas are the most common primary
malignant brain tumours in humans. They are charac-
terized by widespread distribution throughout CNS, dif-
fuse and infiltrative growth pattern, and inherent trend
to undergo malignant transformation. In general the
prognosis is poor despite progress in tumour imaging
and treatment.
Histopathologic diagnosis is essential for optimal
prognostication and treatment. According to World
Health Organization (WHO), diffuse astrocytomas can
be divided into diffuse astrocytoma grade II, anaplastic
astrocytoma grade III, and glioblastoma grade IV [1].
Distinction between different tumour grades can be
challenging, and limited tumour material is often pro-
vided to the pathologist. The number of mitoses is of
paramount importance, but can be hard to identify in
haematoxylin and eosin (H&E)-stained sections [2].
S i n c ep r o l i f e r a t i v ea c t i v i t yi sar e l i a b l em e t h o dt o
assess tumour biology, there has been continuous
research to find such biological markers. Commonly
used is the monoclonal antibody Ki-67/MIB-1 which
has proven prognostic and diagnostic power in astrocy-
tic tumours [3,4]. Nevertheless, the application of this
antibody is hampered by lack of standardization of the
immunohistochemical procedures, significant interla-
boratory variability, and considerable overlap between
the different malignancy groups [3,4].
New antibodies reactive against proliferation-associated
antigens have been launched and shown to correlate with
tumour grade, mitoses, and Ki-67/MIB-1 [5-12]. The
core histone protein H3 constitutes a major part of the
* Correspondence: andrehab@stud.ntnu.no
1Department of Laboratory Medicine, Children’s and Women’s Health,
Norwegian University of Science and Technology, Trondheim, Norway
Full list of author information is available at the end of the article
Habberstad et al. Diagnostic Pathology 2011, 6:43
http://www.diagnosticpathology.org/content/6/1/43
© 2011 Habberstad et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.chromatin and is phosphorylated during mitosis [13,14].
There are reports on the phosphorylated form of histone
H3 (pHH3) at serine 10 and its potential clinical role and
prognostic value in astrocytomas [5,6].
A n o t h e rm a r k e ri ss u r v i v i n ,am e m b e ro ft h ei n h i b i -
tor-of-apoptosis-family, which promotes survival of
tumour cells [7,15]. It is commonly expressed in
embryonic and neoplastic tissues and barely expressed
in normal cells [16]. There is limited experience with
survivin immunostaining and prognosis in anaplastic
astrocytomas, and conflicting data exist in glioblastomas
[8,17,18]. Even the significance of the subcellular locali-
zation of this protein appears uncertain [6,17-19].
Further, survivin may promote radiation resistance in
glioblastomas [20,21].
Nuclear DNA topoisomerase IIa (TIIa)s e r v e sa sa n
essential enzyme with important function in DNA topol-
ogy, repair, and replication, and proliferative signals may
upregulate the gene expression [22,23]. TIIa immunos-
taining in high grade astrocytomas has been shown to
represent a reliable proliferation marker and to provide
valuable prognostic information [8-12,24].
Mitosin, also called p330d/CENP-F, is linked with the
centromere/kinetochore complex and is expressed dur-
ing the active phases of the cell cycle with a maximum
in G2 and M [25,26]. Increased expression is associated
with malignancy grade and survival of astrocytomas
[12], however, there are few studies to support this
finding.
It appears that current proliferation markers to vary-
ing degree hold prognostic significance in human astro-
cytic tumours, however, the experience in anaplastic
astrocytomas is limited. The goal of the present study
was to evaluate and compare these novel proliferation
markers and consider their prognostic value in a series
of anaplastic astrocytomas.
Materials and methods
This study is an extension of a recently published study
[27]. A total number of 27 patients with supratentorial
anaplastic astrocytomas operated at the Department of
Neurosurgery, St. Olav’s University Hospital, Trond-
heim, Norway, in the time period 1998-2006, were
included. The extent of tumour resection was deter-
mined by postoperative MRI scans. Surgical resection
was defined as gross total resection, partial resection, or
biopsy. The clinical data were obtained from electronic
medical records and included age, sex, symptoms at pre-
sentation, tumour localization, treatment modalities, and
postoperative survival. Preoperative Karnofsky perfor-
mance status (KPS) score was retrospectively deter-
mined from a routine neurological examination from
patient admittance.
The tumour samples consisted of both formalin-fixed
and paraffin-embedded cryosections and unfrozen tissue.
All haematoxylin and eosin (H&E) stained sections were
reviewed by an experienced neuropathologist (SHT),
and tumour grading was based on the latest WHO
scheme [1]. The commercial antibodies used are shown
in Table 1. Four μm thick sections with representative
tumour tissue were incubated with primary antibodies
after quenching of endogenous peroxidase activity with
3% hydrogen peroxyde and antigen retrieval by pressure
cooking. The immunostaining was carried out on a
DAKO Autostainer (Dako, Glostrup, Denmark). Visuali-
zation of immunoreactivity was performed with DAKO
EnVision system with diaminobenzidin as chromogene.
Sections were counterstained with haematoxylin. Posi-
tive controls were included in each staining run (human
tonsils).
For the microscopical analyses a Nikon Eclipse
80i was used. All immunostained sections were
scanned for the most densely labelled areas, and calcu-
lations were done with the 40x objective, termed
microscopic high power fields (HPF), using an ocular
grid (0.058 mm
2).
Mitotic activity was defined as the number of mitoses
in ten consecutive HPFs, whereas mitotic index was cal-
culated as the percentage of mitoses using the ocular
grid. In several tumour samples mitotic counting was
Table 1 Antibodies and immunohistochemical procedures
Antibody Source Type Clone Positive
control
Dilution Incubation
temperature
Incubation
time
Ki-67/MIB-1 Dako, Glostrup, DK Monoclonal Ki-67
antigen
Tonsil 1:100 Room temperature 40 min
PHH3 Upstate Biotechnology. Millipore,
Billerica, USA
Polyclonal H3 (Ser10) Tonsil 1:2000 Room temperature 60 min
Survivin Abcam Products,
Cambridge, MA, USA
Monoclonal EP2880Y Tonsil 1:250 Room temperature 40 min
Mitosin Novus Biologicals, LTD,
Cambridge, UK
Monoclonal 14C10/1D8 Tonsil 1:500 Room temperature 40 min
DNA
topoisomerase IIa
Dako, Glostrup, DK Monoclonal KiS1 Tonsil 1:100 Room temperature 40 min
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sies. Cells with positive pHH3 staining were recorded in
the same way as mitoses, including only positively
stained nuclei with chromatin changes equivalent to
mitotic division.
Antibodies against Ki-67, pHH3, survivin, mitosin,
and TIIa displayed immunoreactive tumour cell nuclei
(Figure 1). Only distinctly stained nuclei were counted.
The labelling index (LI) was determined by counting at
least 1000 tumour cells in the ocular grid in one HPF. If
this number of tumour cells could not be obtained,
t h r e eH P F sw e r ee x a m i n e d .T h ep r o l i f e r a t i v ei n d e xw a s
defined as the percentage of immunoreactive tumour
cells out of the total number of cells. This part of the
study was executed blindly from any clinical informa-
t i o n ,a n dt h ed a t aw e r ee v a l u a t e db ys p o tt e s t so ft h e
results from two independent scientists (SHH and
AHH). Regarding survivin immunostaining, the applied
monoclonal antibody was reactive against both cytoplas-
mic and nuclear located protein and we recorded only
the latter.
Statistical analyses were assessed using SPSS version
17.0 (SPSS Inc., Chicago, IL) Correlations between vari-
ables were identified employing the Spearman’sr a n k
correlation (Spearman’s rho), survival data by using
Kaplan-Meier curves, log rank-, and COX regression
test. Cut points for the different variables were set
according to the literature or at the median. The p
value, from which statistical significance was assumed,
was set to p < 0.05.
The study was approved by the Regional Committee
for Medical Research Ethics and protocols followed the
guidelines by the Helsinki Declaration.
Results
General
Twenty-seven patients (10 women and 17 men; median
age, 49 yr; age range, 28-78 yr; median KPS, 70; KPS
range, 50-90) with anaplastic astrocytomas were
included in the study. Clinical data are presented in
Table 2. Four of the patients had previously undergone
brain surgery for diffuse astrocytoma (WHO grade II).
Proliferative markers
Immunohistochemical data and estimates for mean
values for the proliferative markers are shown in Table 3.
Correlation computed by the Spearman’sr h o ,s h o w e d
significant correlation between most of the proliferative
markers (Table 4). Only survivin correlated significant to
mitotic activity. The strongest correlations were seen
between survivin and the pHH3 index (rs = 0.779, p <
0.001), survivin and Ki-67/MIB-1 (rs = 0.666, p < 0.001),
survivin and mitosin (rs= 0.627, p = 0.001), TIIa and
pHH3 mitoses/10HPF (rs = 0.611, p = 0.001), survivin
and TIIa (rs= 0.552, p = 0.003), and between mitosin and
Ki-67/MIB-1 (rs = 0.558, p = 0.005).
Survival
The median survival was 2.4 years (95% CI, 8-48
months). The one-year survival was 73%. Univariate
Figure 1 Proliferation markers in anaplastic astrocytomas. Mitotic figures (arrows) in H&E-stained sections (A). Nuclear immunoreactivity of
Ki-67/MIB-1(B), pHH3 stained mitotic figure (arrow) (C), survivin (D), TIIa (E), and mitosin (F).
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variable, demonstrated significant correlation to KPS (p
< 0.001), tumour surgery (p < 0.001), age (p = 0.016),
pHH3 index (p = 0.018), and Ki-67/MIB-1 (p = 0.031).
Gross total resection and higher KPS independently cor-
related with overall survival (p = 0.026 and p = 0.001
respectively) in a multivariate COX analysis.
Log-rank tests and Kaplan-Meier curves were com-
puted for the cut off values of each proliferation marker.
Overall survival (OS) was the dependent variable. Ki-67/
MIB-1 ≤10 versus >10 (mean OS = 58 vs. 25 months, p
= 0.034) and TIIa ≤4v e r s u s> 4( m e a nO S=6 5v s .2 6
months, p = 0.009) resulted in significant differences
(Figure 2), while pHH3 index ≤0.8 versus >0.8 showed a
trend (p = 0.089). The other proliferative markers did
not reach statistical significance.
Discussion
In astrocytomas proliferative activity has been positively
correlated to tumour grade and prognosis. Small biop-
sies and intricate histology make diagnosing difficult,
and reliable biological markers are highly needed. In this
immunohistochemical study, we demonstrated positive
correlation between the proliferation markers Ki-67/
MIB-1, mitosin, survivin, pHH3, and DNA topoisome-
rase IIa. Furthermore, Ki67/MIB-1 and pHH3 indicated
poorer survival in univariate analyses.
Mitotic activity is fundamental in the histopathologic
grading of human astrocytomas. Identification of mitotic
figures is hampered by several factors including squeezed
cells in stereotactic biopsies, distortion and similarities to
chromatin changes in apoptotic and pycnotic cells [2]. We
experienced such elements, particularly in small biopsies
and in paraffin sections prior used in frozen sections diag-
nostics. In contrast to others [5,6,28,29] we did not find
positive correlations between mitoses and most of the pro-
liferative markers, probably because of the above men-
tioned factors. Hence, this observation suggests that
antibodies against proliferation-associated antigens are
useful to obtain an optimal profile of the proliferative
activity, especially in small brain tumour samples.
Ki-67/MIB-1 immunostaining worked well and yielded
credible results in our study. The LIs displayed a wide
range of values that overlap with indices in both grade
Table 2 Patient characteristics
Case no. Age (years)/Sex Prior brain tumour KPS
1 Resection grade Radiotherapy Postoperative survival (months)
1 28/F
2 No 90 GTR
3 1.8 Gy × 30 54.6
2 32/F No 70 Partial 2.0 Gy × 30 16.0
3 34/F No 80 Partial 1.8 Gy × 30 29.0
4 34/F No 80 Partial 1.8 Gy × 30 94.4+
4
5 36/M
5 No 70 Partial 3.0 Gy × 13 11.1
6 37/M No 80 GTR No 53.8+
7 38/M No 80 Partial 2.0 Gy × 30 34.8+
8 39/F No 70 GTR N.D.
6 N.D.
9 42/M No 70 GTR 1.8 Gy × 30 92.3+
10 44/F No 80 GTR No 58.9+
11 44/M Low-grade glioma 90 Partial No 40.9
12 44/M Low-grade glioma 80 Partial 1.8 Gy × 30 29.0+
13 47/M Low-grade glioma 90 GTR No 88.8+
14 49/M No 50 Biopsy No 0.1
15 49/M No 70 Partial 2.0 Gy × 30 30.2+
16 50/M Low-grade glioma 80 Partial 1.8 Gy × 30 23.4
17 53/M No 70 Partial 1.8 Gy × 30 24.3
18 56/F No 70 Partial 2.0 Gy × 30 17.6
19 57/F No 70 Partial 1.8 Gy × 30 5.5
20 57/F No 80 Partial 1.8 Gy × 30 62.9+
21 57/M No 80 Partial 1.8 Gy × 30 16.4
22 58/M No 80 Partial 1.8 Gy × 30 28.2
23 64/M No 70 GTR 1.8 Gy × 30 75.0+
24 71/M No 50 Biopsy 3.0 Gy × 13 10.1
25 72/M No 60 Biopsy 1.8 Gy × 30 10.9
26 78/F No 50 Biopsy 3.0 Gy × 13 9.7
27 78/M No 50 Biopsy No 1.8
1KPS = Karnofsky Performance Status,
2F = Female,
3GTR = Gross total resection,
4(+) denotes that the patient is still alive,
5M = Male,
6N.D. = No data.
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main reason for Ki-67/MIB-1 not being included in the
routine histopathological diagnosis of astrocytic tumours
[1]. Thus, this marker should not be used alone, but in
combination with established histopathological criteria
of malignancy.
Proposals for clinical threshold values have been sug-
gested [3] without a consensus being reached. Using a
value of 10% [3,7] a significant impact on survival was
found, verifying this as a reasonable threshold.
pHH3 is a novel promising proliferation marker in
tumour pathology, however the experience in astrocytomas
is limited. In our hands, this antibody provided reliable
immunostaining with distinct nuclear positivity in cells
with mitotic morphology. Positive correlations with the
other proliferative markers were found except mitoses.
This discrepancy may be due to the problem to identify
mitotic figures in squeezed and small biopsies. Comparison
between the number of mitoses and pHH3 positive nuclei,
revealed the latter to be higher, in accordance with being a
more sensitive marker for mitoses [5,14,29,30]. A major
drawback of the pHH3 immunostaining seems to be posi-
tivity in non-mitotic cells [14]. This, together with the sub-
jective determination of mitotic morphology, may lead to
Table 3 Results of the immunohistochemical analyses of the proliferation markers
Case no. Mitoses/10HPF Mitotic index Ki-67/
MIB-1
PHH3 mitoses/
10HPF
PHH3 index TIIa Survivin Mitosin
1 N.D.
1 N.D. 6.8 1 0.5 1.8 2 2.4
2 0 0 3.5 1 1.7 2.5 2.7 8.5
3 15 0.9 6.8 19 0.9 10.8 5.3 3.4
4 1 0.6 9.2 18 0.9 7.9 7.5 8.6
5 0 0 19.0 6 2.2 0 5.8 3.6
6 2 0.4 9.2 2 0.6 2 3.4 3.1
7 0 0 1.0 0 0.0 0.8 0.3 0
8 1 0.6 7.9 1 0.8 2.7 3.3 3.5
9 0 0 5.0 1 0.2 0 2.4 2.5
10 0 0 2.1 3 0.6 0 1.9 1.8
11 N.D. N.D. 6.4 10 1.3 25 3.7 1.5
12 0 0 4.2 4 1.0 4 2.7 1.9
13 N.D. N.D. 4.4 4 0.6 1.8 1.2 1.1
14 N.D. N.D. 8.5 8 0.8 5 2.6 3.4
15 6 0.5 22.2 9 1.1 8.2 6 3.8
16 N.D. N.D. 8.6 1 0.5 6.1 2.5 8
17 1 0.7 N.D. N.D. N.D. 4.5 3.8 2.9
18 N.D. N.D. 15.0 5 1.9 6 4.4 2.7
19 0 0 20.0 2 0.4 5.4 2.3 1.4
20 N.D. N.D. 3.2 1 0.1 1.4 1.5 N.D.
21 N.D. N.D. 16.4 30 1.1 6.9 3.5 4.5
22 2 0.5 4.0 5 0.8 3.7 3.5 1.2
23 1 0.8 12.9 15 2.0 0 6.1 2.7
24 N.D. N.D. 4.9 16 1.5 2 2 2
25 0 0 16.5 24 1.7 11 8.9 5.1
26 0 0 10.2 19 0.6 6.3 2.6 N.D.
27 13 0.7 21.0 37 2.7 13.5 9.6 9.5
Median 0.5 0.2 8.2 5 0.8 4 3.3 2.9
Minimum 0 0 1 0 0 0 0.3 0
Maximum 15 0.9 22.2 37 2.7 25 9.6 9.5
Mean 2.3 0.3 9.6 9.3 1.0 5.2 3.8 3.6
Std. deviation 4.5 0.3 6.3 10.0 0.7 5.4 2.3 2.5
Variance 20.2 0.1 39.6 100.2 0.5 28.9 5.2 6.4
1N.D. = No Data
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were associated with poorer survival in univariate analyses
in accordance with others [5]. For this reason pHH3 stands
out as a reliable biomarker, however, larger studies are
necessary to further elucidate this observation.
Survivin immunoreactivity was located both in the
cytoplasm and in the nucleus, as described by others
[6,8,18]. The nuclear positivity was in contrast to the
cytoplasmatic staining, easily detectable and distinct. As
the localization of survivin compartments in the nucleus
is correlated to cell division and prognosis [6,17,19],
only the nuclear positivity was included. Survivin
expression showed significant positive correlation with
all of the proliferation markers, suggesting that nuclear
survivin positivity can be a reliable proliferation marker
in astrocytic tumours. Our data demonstrated no corre-
lation between survivin expression and survival. The lit-
erature is contradictory in this matter [8,17-19], and
larger studies are needed to clarify this topic. The effect
of survivin on radiotherapy resistance is intriguing. If,
however, radiotherapy effects depend on the presence or
not of survivin, the implication in anaplastic astrocyto-
mas can be limited, as all of the tumours in our material
displayed positively stained cells.
The results from our TIIa immunostaining corre-
lated well to the other proliferation markers, in
Table 4 Relationships between the proliferation markers (Spearman’s rank correlation)
Mitoses/10HPF
Mitotic index rs .864
1 Mitotic index
p value 0.000
Ki-67/MIB-1 rs .292 .238 Ki-67/MIB-1
p value 0.255 0.358
PHH3 mitoses
/10HPF
rs .402 .404 .543 PHH3 mitoses/10HPF
p value 0.110 0.108 0.015
PHH3 index rs .320 .361 .470 .661 PHH3 index
p value 0.211 0.154 0.015 0.000
TIIa rs .430 .303 .479 .611 .352 TIIa
p value 0.075 0.222 0.013 0.001 0.078
Survivin rs .582 .588 .666 .672 .779 .552 Survivin
p value 0.011 0.010 0.000 0.000 0.000 0.003
Mitosin rs .312 .261 .558 .372 .475 .443 .627
p value 0.223 0.311 0.005 0.074 0.019 0.027 0.001
1 p value < 0,05 is highlighted
Figure 2 Kaplan-Meier survival curves. KI-67/MIB-1 (mean OS = 58 vs. 25 months) (A). TIIa (mean OS = 65 vs. 26 months) (B).
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of positively stained nuclei was easily calculated, and
was in general of a lower value than the values of
Ki-67/MIB-1, as seen in previous studies [11,24]. This
result could be explained by the different protein
expression throughout the cell-cycle. TIIa positive
cells in G0- and G1 phase have been reported [9], and
may represent a drawback of this marker. Using the
median of 4% as a cut-point, TIIa was significantly
associated with survival in our material. This is in
accordance with others using similar cut-points [9]
and suggests that TIIa could be of prognostic value in
astrocytic tumours.
Mitosin also displayed significant correlations to all of
the proliferative markers, which is in accordance with
studies on other malignancies [26]. Immunoreactive
nuclei were easily identified and can be explained by the
mitosin expression in S-, G2-, and M phase, and its
rapid degradation [25,26]. Our study could not correlate
mitosin expression significantly to survival.
Due to the small number of cases, the survival ana-
lyses have been carefully interpreted. However, univari-
ate analyses have gathered sense of which markers that
could be further investigated in well-designed studies
for prognostic relevance.
The caveats of immunohistochemical analyses include
different antibodies, different antigens, background
staining, and inhomogeneous staining that can contri-
bute to interlaboratory and interobserver variations.
Wrong assumptions can also be made as the knowledge
of the novel markers is limited. For instance, protein
overexpression in tumour cells can represent genetic
aneuploidity, mutated genes or increased transcription
factors. Additionally, the functions of a proliferative
marker may not exclusively be related to the cell cycle,
as was the case for the proliferating cell nuclear antigen
(PCNA) [31].
Variations in immunoreactivity may be due to differ-
ent expression during the cell cycle. The recorded wide
range of values represents a major drawback of such
markers as one will experience considerable overlap
between malignancy groups. Thus, one should consider
the possibility to introduce a panel of proliferation mar-
kers to identify more aggressive astrocytomas.
Conclusion
In conclusion, immunohistochemical determination of
proliferative activity in anaplastic astrocytomas using
antibodies against Ki-67 antigen, survivin, mitosin,
pHH3 and DNA topoisomerase IIa,m a ya s s i s ti nt h e
histopathological diagnosis, especially because mitoses
can be hard to detect. The prognostic value requires
further investigation.
Acknowledgements
The authors want to thank Eli Johannessen, Unn S. Granli, and Borgny
Ytterhus for skilful technical assistance.
Author details
1Department of Laboratory Medicine, Children’s and Women’s Health,
Norwegian University of Science and Technology, Trondheim, Norway.
2Department of Neurosurgery, St. Olav’s University Hospital, Trondheim,
Norway.
3Department of Pathology and Medical Genetics, St. Olav’s
University Hospital, Trondheim, Norway.
Authors’ contributions
AHH participated in the immunohistochemical and the statistical analyses,
and drafted the manuscript. SG collected clinical information, performed
statistical analyses and participated in the design of the study and to draft
the manuscript. SHT conceived of the study and participated in its design,
coordination and immunohistochemical analyses and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 April 2011 Accepted: 24 May 2011 Published: 24 May 2011
References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A,
Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of
the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Prayson RA: Cell proliferation and tumors of the central nervous system.
Part 1: Evaluation of mitotic activity. J Neuropathol Exp Neurol 2002,
61:501-509.
3. Johannessen A, Torp S: The clinical value of Ki-67/MIB-1 labeling index in
human astrocytomas. Pathol Oncol Res 2006, 12:143-147.
4. Prayson RA: The utility of MIB-1/Ki-67 imunostaining in the evaluation of
central nervous system neoplasms. Adv Anat Pathol 2005, 12:144-148.
5. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G,
Langford L, Pelloski C, Aaron J, et al: Assessment and prognostic
significance of mitotic index using the mitosis marker phospho-histone
H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg
Pathol 2006, 30:657-664.
6. Liu X, Chen N, Wang X, He Y, Chen X, Huang Y, Yin W, Zhou Q: Apoptosis
and proliferation markers in diffusely infiltrating astrocytomas: profiling
of 17 molecules. J Neuropathol Exp Neurol 2006, 65:905-913.
7. Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H,
Asoh S, Teramoto A, Ohta S: Prognostic significance of the
immunohistochemical index of survivin in glioma: a comparative study
with the MIB-1 index. J Neurooncol 2005, 72:231-238.
8. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rossler K, Budka H,
Hainfellner JA: No prognostic impact of survivin expression in
glioblastoma. Acta Neuropathol 2005, 109:534-538.
9. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A,
Nakashima N, Yoshida J: Immunohistochemical staining of DNA
topoisomerase IIalpha in human gliomas. J Neurosurg 1999, 91:477-482.
10. Faria MH, Goncalves BP, do Patrocinio RM, de Moraes-Filho MO,
Rabenhorst SH: Expression of Ki-67, topoisomerase IIalpha and c-MYC in
astrocytic tumors: correlation with the histopathological grade and
proliferative status. Neuropathology 2006, 26:519-527.
11. Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I, Strobel T,
Rossler K, Budka H, Hainfellner JA: High expression of DNA topoisomerase
IIalpha and Ki-67 antigen is associated with prolonged survival in
glioblastoma patients. Eur J Cancer 2002, 38:1343-1347.
12. Korkolopoulou P, Patsouris E, Konstantinidou AE, Christodoulou P,
Thomas-Tsagli E, Kouzelis K, Angelidakis D, Rologis D, Davaris P: Mitosin
and DNA topoisomerase IIalpha: two novel proliferation markers in the
prognostication of diffuse astrocytoma patient survival. Appl
Immunohistochem Mol Morphol 2001, 9:207-214.
13. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H,
Darzynkiewicz Z: Histone H3 phosphorylation and expression of cyclins A
and B1 measured in individual cells during their progression through G2
and mitosis. Cytometry 1998, 32:71-77.
Habberstad et al. Diagnostic Pathology 2011, 6:43
http://www.diagnosticpathology.org/content/6/1/43
Page 7 of 814. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR,
Bazett-Jones DP, Allis CD: Mitosis-specific phosphorylation of histone H3
initiates primarily within pericentromeric heterochromatin during G2
and spreads in an ordered fashion coincident with mitotic chromosome
condensation. Chromosoma 1997, 106:348-360.
15. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC:
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature
1998, 396:580-584.
16. Li F: Survivin study: what is the next wave? J Cell Physiol 2003, 197:8-29.
17. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J, Itoh H, Ishiuchi S,
Sakurai H, Hasegawa M, Nakano T: Nuclear survivin expression predicts
poorer prognosis in glioblastoma. J Neurooncol 2009, 91:353-358.
18. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T,
Arita K, Kurisu K: Survivin subcellular localization in high-grade
astrocytomas: simultaneous expression in both nucleus and cytoplasm is
negative prognostic marker. J Neurooncol 2007, 82:193-198.
19. Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic
expression of survivin: what is the significance? Int J Cancer 2005,
114:509-512.
20. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA,
Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation
resistance in primary human glioblastoma cells via caspase-independent
mechanisms. Oncogene 2004, 23:7494-7506.
21. McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary JP,
Moumdjian R, Beliveau R: The Survivin-mediated radioresistant phenotype
of glioblastomas is regulated by RhoA and inhibited by the green tea
polyphenol (-)-epigallocatechin-3-gallate. Brain Res 2006, 1071:1-9.
22. Watt PM, Hickson ID: Structure and function of type II DNA
topoisomerases. Biochem J 1994, 303(Pt 3):681-695.
23. Larsen AK, Skladanowski A, Bojanowski K: The roles of DNA topoisomerase
II during the cell cycle. Prog Cell Cycle Res 1996, 2:229-239.
24. Ho DM, Hsu CY, Ting LT, Chiang H: MIB-1 and DNA topoisomerase II
alpha could be helpful for predicting long-term survival of patients with
glioblastoma. Am J Clin Pathol 2003, 119:715-722.
25. Zhu X, Mancini MA, Chang KH, Liu CY, Chen CF, Shan B, Jones D,
Yang-Feng TL, Lee WH: Characterization of a novel 350-kilodalton nuclear
phosphoprotein that is specifically involved in mitotic-phase
progression. Mol Cell Biol 1995, 15:5017-5029.
26. Varis A, Salmela AL, Kallio MJ: Cenp-F (mitosin) is more than a mitotic
marker. Chromosoma 2006, 115:288-295.
27. Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH:
Overexpression of c-erbB2 is a negative prognostic factor in anaplastic
astrocytomas. Diagn Pathol 2010, 5:18.
28. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ,
Forsyth PA, Hayostek CJ: Cellular proliferation in pilocytic and diffuse
astrocytomas. J Neuropathol Exp Neurol 1999, 58:46-53.
29. Ladstein RG, Bachmann IM, Straume O, Akslen LA: Ki-67 expression is
superior to mitotic count and novel proliferation markers PHH3, MCM4
and mitosin as a prognostic factor in thick cutaneous melanoma. BMC
Cancer 2010, 10:140.
30. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN: The mitosis-
specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid
reliable grading of meningiomas according to WHO 2000 criteria.
Am J Surg Pathol 2004, 28:1532-1536.
31. McCormick D, Hall PA: The complexities of proliferating cell nuclear
antigen. Histopathology 1992, 21:591-594.
doi:10.1186/1746-1596-6-43
Cite this article as: Habberstad et al.: Evaluation of the proliferation
markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase
IIa in human anaplastic astrocytomas - an immunohistochemical study.
Diagnostic Pathology 2011 6:43.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Habberstad et al. Diagnostic Pathology 2011, 6:43
http://www.diagnosticpathology.org/content/6/1/43
Page 8 of 8